Alnylam Pharmaceuticals are trading higher amid possible continued strength after the company yesterday announced topline results from its HELIOS-B Phase 3 study of vutrisiran. Also, multiple firms raised their respective price targets on the stock.
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals' stock is trading higher following the announcement of positive topline results from its HELIOS-B Phase 3 study of vutrisiran. Additionally, several firms have raised their price targets for the stock.
June 25, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam Pharmaceuticals' stock is experiencing an upward trend due to positive topline results from its HELIOS-B Phase 3 study of vutrisiran. The stock is further supported by multiple firms raising their price targets.
The positive results from the HELIOS-B Phase 3 study of vutrisiran are a significant milestone for Alnylam Pharmaceuticals, likely boosting investor confidence. The subsequent price target upgrades by multiple firms further reinforce the positive sentiment, making a short-term price increase highly probable.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100